{"id":169493,"date":"2024-06-03T02:37:26","date_gmt":"2024-06-03T06:37:26","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/telix-completes-tlx250-cdx-zircaix-bla-submission-for-kidney-cancer-imaging\/"},"modified":"2024-08-18T11:48:28","modified_gmt":"2024-08-18T15:48:28","slug":"telix-completes-tlx250-cdx-zircaix-bla-submission-for-kidney-cancer-imaging","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/telix-completes-tlx250-cdx-zircaix-bla-submission-for-kidney-cancer-imaging.php","title":{"rendered":"Telix Completes TLX250-CDx (Zircaix\u2122) BLA Submission for Kidney Cancer Imaging"},"content":{"rendered":"<p><![CDATA[MELBOURNE, Australia, June  03, 2024  (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has completed the submission of a Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for its investigational radiodiagnostic PET1 agent, TLX250-CDx (Zircaix\u21222, 89Zr-DFO-girentuximab), for the characterisation of renal masses as clear cell renal cell carcinoma (ccRCC).]]><\/p>\n<p>Read the original:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2024\/06\/02\/2891867\/0\/en\/Telix-Completes-TLX250-CDx-Zircaix-BLA-Submission-for-Kidney-Cancer-Imaging.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Telix Completes TLX250-CDx (Zircaix\u2122) BLA Submission for Kidney Cancer Imaging\">Telix Completes TLX250-CDx (Zircaix\u2122) BLA Submission for Kidney Cancer Imaging<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Read the original: Telix Completes TLX250-CDx (Zircaix\u2122) BLA Submission for Kidney Cancer Imaging <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/telix-completes-tlx250-cdx-zircaix-bla-submission-for-kidney-cancer-imaging.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-169493","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/169493"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=169493"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/169493\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=169493"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=169493"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=169493"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}